Read More

Extend Life Expectancy Against Aggressive Brain Cancers – Nano-Cap Firm Biodexa’s Investigational Drug Shows Potential

Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and Recurrent Glioblastoma patients. Learn more about MTX110's potential.

BDRX